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Abstract
Background: To access the prognostic significance of HER-2 overexpression, the effect of trastuzumab and the
cause of death in patients with brain metastases (BM) from breast cancer (BC).
Methods: We analyzed the outcome of 130 patients with BM from BC who received whole-brain radiotherapy
(WBRT) (without surgery or radiosurgery) between January 1998 and April 2006. Demographic data, tumor
characteristics, and treatments were prospectively recorded. The impact of HER-2 overexpression and trastuzumab-
based therapy on overall survival (OS) and the cause of death were evaluated.
Results: The median follow-up for the whole population was 6.25 months (mean: 9.15; range: 0.23-53). The median
survival time and 1-year survival rates after BM diagnosis were 7.43 months and 35.8% (95% CI: 28-45.7)
respectively. The median survival time for HER-2 negative patients (n = 78), HER-2 positive patients not treated with
trastuzumab (n = 20) and HER-2 positive patients treated with trastuzumab (n = 32) were 5.9 months, 5.6 months
and 19.53 months, respectively. The 1-year survival rates were 26.1%, 29.2% and 62.6% respectively, (p < 0.004).
Among the 18 HER-2 positive patients treated with trastuzumab who died, 11 (61%) apparently succumbed from
CNS progression, in the face of stable or responsive non-CNS disease. Trastuzumab-based therapy was associated
with a 51% reduction in the risk of death (multiadjusted hazard ratio: 0.49; 95% CI, 0.29-0.83).
Conclusions: In our experience, trastuzumab-based therapy for HER-overexpressing tumors was associated with
improved survival in BM BC patients. This subgroup of patients may benefit from innovative approaches, in order
to obtain better intra cerebral control.
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Background
About 10% to 30% of patients with metastatic breast
cancer develop brain metastases (BM) [1]. Several
reports suggest that the risk of developing BM is higher
(25% to 40%] in patients receiving trastuzumab-based
therapy for HER2-overexpressing metastatic breast can-
cer [2-9]. Whole-brain radiotherapy (WBRT] is consid-
ered the standard treatment for most patients,
particularly those with extensive intra-cranial disease,
providing symptom relief and prolonging both median
and overall survival (1,10-12). Despite the use of WBRT,
the prognosis of patients with BM remains poor, with a
median survival time of approximately 5 months
[1,10-14]. Recent studies have examined the influence of
patient characteristics on survival in this setting and
have attempted to identify subgroups of patients with
substantially different outcomes in order to tailor ther-
apy and to rationalize the design, stratification and
interpretation of clinical trials [13-19]. The Radiation
Therapy Oncology Group (RTOG] recursive partitioning
analysis (RPA) classification based on clinical factors
(Karnofsky performance status, age, and control of
extracerebral disease) is a major prognostic indicator for
patients with brain metastases [13]. Several reports
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cancer patients with BM fare better than HER2-negative
breast cancer patients and patients with HER2-positive
tumors who do not receive trastuzumab [20-26]. The
prognostic significance of HER-2 overexpression and
trastuzumab-based therapy has not been analyzed in the
previously published prognostic scores of patients with
brain metastases. The aim of this study was to confirm,
in a cohort of patients with BM from breast carcinoma,
the beneficial effect of trastuzumab in patients with
HER2-positive disease, and to analyze the cause of
death.
Methods
Patients and treatments
Between January 1998 and April 2006, 195 consecutive
breast cancer patients with BM were treated at Institut
Curie-Hôpital René Huguenin Cancer Center, Saint
Cloud, France. The study population consisted of 130
patients who received whole brain radiation therapy
(WBRT) (without surgery or radiosurgery) and whose
tumoral HER-2 status was known. The characteristics of
these 130 patients, their tumors, metastatic sites, and
therapy (chemotherapy, endocrine therapy or trastuzu-
mab-based therapy) were prospectively recorded in the
hospital’s MEDICOD database. Karnofsky performance
status (KPS) (< 70 vs ≥ 70), the Radiation Therapy
Oncology Group (RTOG) recursive partition analysis
(RPA) class (I-II vs III) [13] and the number of BM (sin-
gle vs multiple) at the time of BM diagnosis were
obtained retrospectively from the medical charts. The
primary tumor was considered to be HER-2-positive
(HER-2+) if it scored 3+ on immunohistochemistry
(IHC), or if it scored 2+ on IHC and showed gene
amplification by fluorescence in situ hybridization
(FISH). Trastuzumab exposure for metastatic disease
before and after BM diagnosis was recorded. All the
patients had computed tomography (CT) and/or mag-
netic resonance imaging (MRI) for BM diagnosis.
WBRT was delivered with a standardized lateral
opposed fields technique that used 6-MV or 10-MV
photons, up to a standard dose of 30 Gy in ten daily 3-
Gy fractions. The patients were seen every month for 6
months after the end of treatment, and then every 2
months. Our institutional review board approved the
acquisition, analysis and reporting of the patients’ data.
Statistical analysis
Patient characteristics were compared by using the chi-
square test or Ficher’s exact test for categorical variables
and by using the T-test or Kruskall Wallis test for the
quantitative variables. Overall survival was defined as
the time from BM diagnosis to the last visit or death.
Survival curves were constructed with the Kaplan Meier
method [27] and compared with the log-rank test. Mul-
tivariate analysis (Cox regression model) tested the fol-
lowing variables for their impact on overall survival: age
at BM diagnosis, KPS (< 70 vs ≥ 70), RTOG RPA class
(I-II vs III), presence of extracranial metastases, sites of
other extracranial metastases (bone vs lung vs liver vs
multiple), number of BM (single vs multiple), interval
between primary tumor and BM diagnosis (< 2 years vs
> 2 years), tumor HR status, lymphocyte count at BM
diagnosis (< 0.7 vs > 0.7 × 10
9/L), HER-2 overexpression
and trastuzumab-based therapy. First, the variables were
obtained in univariate analysis. Then, the multivariate
model was computed with backward step. Differences
with P values < 0.05 were considered statistically
significant.
Results
Patient characteristics and treatments
The characteristics of the 130 eligible patients are
reported in table 1. Briefly, mean age at diagnosis was
52.8 years (median: 52; range: 26-83), and 54 patients
(41.5%) were younger than 50 years. The KPS was ≥ 70
in 62.2% of cases. The median time from breast cancer
d i a g n o s i st oB Md i a g n o s i sw a s4 0 . 6m o n t h s( r a n g e ,0 -
265 months). Fifty-two patients (40%) had tumors that
overexpressed Her-2, and 32 patients had received tras-
tuzumab-based therapy in the metastatic setting.
Patients treated before 2001 were not systematically
treated with trastuzumab. Of these 32 pts, 5 pts stopped
trastuzumab before the diagnosis of BM because of sys-
temic progression, 5 discontinued trastuzumab at the
diagnosis of BM and 22 continued a trastuzumab-based
therapy after WBRT.
At BM diagnosis, patients with HER2-overexpressing
breast cancer treated with trastuzumab-based therapy (n
= 32), compared with HER-2 negative patients (n = 78)
and HER-2 positive patients not treated with trastuzu-
mab-based therapy (n = 20), were younger (median
age:47 vs 54 and 53, respectively; p = 0.01), had a better
Karnofsky performance status (KPS ≥ 70: 80.6% vs
57.9% vs 50%, respectively; p = 0.04) and were thus less
likely to be RTOG RPA class III, were more likely to
have liver metastases (71.88% vs 44.87% vs 60%, respec-
tively; p = 0.02) and were more likely to have received
chemotherapy, including taxane-based chemotherapy,
for metastatic breast cancer, respectively (table 1). The
median dose of WBRT was 30 Gy, in ten 3-Gy daily
fractions (mean, 28.1 Gy; range, 3-40 Gy), distributed as
follows: 112 patients received 30 Gy in 10 fractions; 13
patients received < 30 Gy in 3-Gy daily fractions; and 5
patients received > 30 Gy in 2-Gy daily fractions. All
but 13 of the patients completed the full course of
WBRT; these 13 patients discontinued treatment
because of deteriorating systemic or brain disease. Most
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Page 2 of 9Table 1 patient characteristics at diagnosis of brain metastases and treatments
Patient and tumor
characteristics
HER-2 negative
patients
HER-2 positive patients not
treated with trastuzumab
HER-2 positive patients treated
with trastuzumab
Whole
population
P value
N = 78 N = 20 N = 32 N = 130
-60% -15.38% -24.62%
Age at BM diagnosis (years)-
median (range)
< 65 years 54(34-83) 53 (33- 75) 47(26-67) 52(26-83) 0.0178
≥ 65 years 59/77 (76.62) 15/20 (75) 31/32 (96.88) 105/129
(81.4)
18/77 (23.38) 5/20 (25) 1/32 (3.12) 24/129
(18.6)
Karnofsky performance
status
< 70 32/76 (42.11) 10/20 (50) 6/31 (19.35) 48/127
(37.8)
0.0418
≥ 70 44/76 (57.89) 10/20 (50) 25/31 (80.65) 79/127
(62.2)
RTOG RPA class 0 0 0 0 0.0391
I 43/75 (57.33) 10/20 (50) 25/31 (80.65) 78/126
(61.9)
II 32/75 (42.67) 10/20 (50) 6/31 (19.35) 48/126
(38.1)
III
Histology of primary BC
Ductal 70/76 (92.11) 19/20 (95) 30/32 (93.75) 119/128
(92.97)
0.5172**
(ns)
Lobular 2/76 (2.63) 0 2/32 (6.25) 4/128 (3.12)
Other 4/76 (5.26) 1/20 (5) 0 5/128 (3.91)
Histologic grade
SBR I 2/70 (2.86) 1/17 (5.88) 1/31 (3.23) 4/118 (3.39) 0.063**
(ns)
SBR II 27/70 (38.57) 1/17 (5.88) 11/31 (35.48) 39/118
(33.05)
SBRIII 41/70 (58.57) 15/17 (88.24) 19/31 (61.29) 75/118
(63.56)
Tumor HR status
Positive 48/76 (63.16) 9/19 (47.37) 17/32 (53.12) 72/127
(56.69)
0.1996
(ns)
Negative 28/76 (36.84) 10/19 (52.63) 15/32 (46.88) 55/127
(43.31)
Number of BM
Single 6/78 (7.69) 0 0 6/130 (4.62) 0.1339**
(ns)
Multiple 72/78 (92.31) 20/20 (100) 32/32 (100) 124/130
(95.38)
0.1778 **
(ns)
Meningitis 17/77 (22.08) 1/20 (5) 4/31 (12.9) 22/128
(17.19)
Yes 60/77 (77.92) 19/20 (95) 27/31 (87.1) 106/128
(82.81)
No
Number of other metastatic
sites
0 (BM alone) 6/78 (7.69) 1/20 (5) 0 7/130 (5.38) 0.2971**
(ns)
1 19/78 (24.36) 3/20 (15) 9/32 (28.12) 31/130
(23.85)
2 20/78 (25.64) 7/20 (35) 14/32 (43.75) 41/130
(31.54)
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Page 3 of 9patients received corticosteroids before WBRT started.
Chemotherapy had been administered to 105 (80.8%)
patients before BM diagnosis.
Patient outcomes
The median follow-up for the whole population was
6.25 months (mean: 9.15; range: 0.23-53). Ninety-eight
patients died (75.4%). The median survival time and the
6-month and 1-year survival rates after BM diagnosis
were 7.43 months (95% CI: 5.52-9.73), 54.9% (95%
CI:46.8-64.3) and 35.8% (95% CI: 28-45.7) respectively.
The median survival time among the 79 patients in RPA
C l a s sI - I Ia tB Md i a g n o s i sw a s9 . 6 3m o n t h s[ 9 5 %C I :
7.69; 15.72], compared with 3.52 months [95% CI: 2.86;
7.36] among the 48 patients in Class III (p = 0.001]. The
median survival time for HER-2 negative patients (n =
78), HER-2 positive patients not treated with trastuzu-
mab (n = 20) and HER-2 positive patients treated with
trastuzumab (n = 32) were 5.9 months, 5.6 months and
19.53 months respectively. The 1-year survival rates
were 26.1% (95% CI: 16.8-40.7), 29.2% (95% CI:17-50.2)
and and 62.6% (95% CI: 47.2-83) respectively, (p <
0.004) (Table 2, Figure 1). The median survival time for
the 10 HER-2 positive patients who stopped trastuzu-
mab before or after the diagnosis of BM and the 22
patients who continued a trastuzumab-based therapy
after WBRT were 9.2 months and 20.9 months respec-
tively (p > 0.1). The 1-year survival rates were 43.6 (95%
CI: 21.8-87.4) and 87.1 (95% CI: 71.8-100), respectively
(p = 0.13).
Table 1 patient characteristics at diagnosis of brain metastases and treatments (Continued)
> 2 33/78 (42.31) 9/20 (45) 9/32 (28.12) 51/130
(39.23)
Concomitant and other
metastases
Liver 35/78 (44.87) 12/20 (60) 23/32 (71.88) 70/130
(53.85)
0.0299
Lung 36/78 (46.15) 11/20 (55) 14/32 (43.75) 61/130
(46.92)
0.7147
(ns)
Bone 51/78 (65.38) 10/20 (50) 18/32 (56.25) 79/130
(60.77)
0.3783
(ns)
Previous chemotherapy 55/78 (70.51) 18/20 (90) 32/32 (100) 105/130
(80.77)
0.0002**
Yes 23/78 (29.49) 2/20 (10) 0 25/130
(19.23)
No
Previous taxane-based
chemotherapy
36/78 (46.15) 11/20 (55) 25/31 (80.65) 72/129
(55.81)
0.0047
Yes 42/78 (53.85) 9/20 (45) 6/31 (19.35) 57/129
(44.19)
No
Lactate Deshydrogenase
(LDH)
35/61 (57.38) 9/14 (64.29) 13/19 (68.42) 57/94
(60.64)
0.6597
(ns)
≤ 500 UI/L 26/61 (42.62) 5/14 (35.71) 6/19 (31.58) 37/94
(39.36)
500 UI/L 127-2088 120-3469 158-2199 120-3469
range
Lymphocyte count 25/70 (35.71) 9/20 (45) 3/20 (15) 37/110
(33.64)
0.1106
(ns)
≤ 0.7 G/L 45/70 (64.29) 11/20 (55) 17/20 (85) 73/110
(66.36)
> 0.7 G/L 61-2285 40-1814 63-2050 40-2285
range
Vital Status 16/78 (20.51) 2/20 (10) 14/32 (43.75) 18/32 (56.25) 32/130
(24.62)
0.0138**
alive 62/78 (79.49) 18/20 (90) 98/130
(75.38)
dead
Abbreviations: BM = brain metastases; BC = breast cancer; SBR = Scarff-Bloom-Richardson grade; HR = hormone receptor; RTOG = Radiation
** Fisher’s exact test
Values are numbers (percentage), unless otherwise stated.
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III, trastuzumab-based therapy for HER-2-overexpres-
sing tumors, a triple-negative phenotype, Scarff-Bloom-
Richardson grade, the serum LDH level and the lympho-
cyte count at BM diagnosis were predictive of overall
survival (Table 3). The following characteristics had no
prognostic value: number of BM, sites of other systemic
metastases, interval between primary tumor and BM
diagnosis, total dose of WBRT, and histology of the pri-
mary breast tumor. Trastuzumab-based therapy for
HER-2-overexpressing tumors and RTOG RPA Class III
or KPS < 70 emerged as independent prognostic factors
in multivariate analysis (table 4). Trastuzumab -based
therapy was associated with a 51% reduction in the risk
of death (multiadjusted hazard ratio [HR] 0.49; 95% CI,
0.29 to 0.83].
Response to WBRT and cause of death
Among the 32 HER-2 positive patients treated with tras-
tuzumab, only 23 pts had at least one follow-up brain
CT scan or MRI by which the radiographic response
could be assessed. Ten patients had CNS progression
and 13 patients had stable intracerebral disease at last
follow-up. The mean PFS in the brain, calculated from
the date of WBRT to the date of brain progression, was
7.4 months (range: 1-18). Among the 18 HER-2 positive
patients treated with trastuzumab who died, 11 (61%)
apparently succumbed from CNS progression, in the
face of stable or responsive non-CNS disease. Only 6
HER2 positive BC patients treated without trastuzumab
and 30 HER-2 negative patients had at least one follox-
up brain CT scan.
Discussion
Because several subgroups of metastatic breast cancer
patients are at a high risk of developing BM [5,9] and
because systemic therapy, particularly trastuzumab, has
limited efficacy for preventing or controlling intracranial
metastases, BM are becoming a major issue in this set-
ting, being associated with poor survival and quality of
life [28,29]. Risk factors for the development of CNS
metastases from breast cancer include patient character-
istics, such as young age and African-American ethni-
city, and biological features of the tumor, including ER-
negativity, HER2-positivity, high tumor grade, and
BRCA1 phenotype [1,7,30-32]. Breast cancer patients
with brain metastases form a heterogeneous population
with respect to their prognosis [14,20-26]. Identification
of patient subgroups with substantially different out-
comes is therefore necessary to tailor therapy and to
help with the design, stratification and interpretation of
future clinical trials. The RTOG RPA classification is
currently recognized as a major prognostic indicator in
patients with brain metastases. It comprises three prog-
nostic classes based on Karnofsky performance status,
age, and control of extracerebral disease [13]. In this
classification, the best survival (RPA Class I), with a
median of 7.1 months, was observed in patients younger
than 65 years of age with a KPS of at least 70, a con-
trolled primary tumor, and metastases restricted to the
brain. The worst survival (RPA Class III), with a median
of 2.3 months, was seen in patients with a KPS below
70. The remaining patients (RPA Class II) had a median
survival of 4.2 months. Several other prognostic scores
for patients with brain metastases from different pri-
maries [14-19] were subsequently developed, but none
of them include molecular features or breast cancer-spe-
cific parameters such as tumor HER-2 overexpression,
nor specific treatments.
Several groups have published retrospective studies
describing improved survival from time of BM diagnosis
in BM patients with HER2-positive BC treated with tras-
tuzumab, compared with HER2-negative breast cancers
[20-26]. In a retrospective study including 56 patients
Table 2 Rates of overall survival at 6 months and 1 year according to the RTOG RPA class, the HER-2 status and the
delivery of trastuzumab
n Median Survival
(months)
6 months
[CI95%]
1 year
[CI95%]
P value
Whole population 130 7.43 (5.52 -9.73) 54.9 [46.8; 64.3] 35.8 [28; 45.7]
RTOG RPA 44.6 [34.3; 58.1] 0.001
Class I-II 78 9.63 (7.69-15.72) 65.9 [56; 77.5] 23.9 [14.2; 40.4]
Class III 48 3.52 (2.86-7.36) 37.7 [26; 54.7]
0.004
HER-2 negative patients 78 5.88 [3.75; 9.63] 48.7 [37.7; 63] 26.1 [16.8; 40.7]
HER-2 positive patients not treated with trastuzumab 20 5.65 [2.60; 12.49] 45.5 [31.3; 66.1] 29.2 [17-50.2]
HER-2 positive patients treated with trastuzumab 32 19.53 [9.27; NA] 77.1 [63.5; 93.6] 62.6 [47.2; 83]
Trastuzumab 10 9.17 (5.52-NA) 63.6 [40.7; 99.5] 43.6 [21.8; 87.4] 0.113
Stopped 22 20.91 (19.53-NA) 94.4 [84.4; 100] 88.5 [74.8; 100]
Continued
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Page 5 of 9with HER2-positive BC who developed BM, Nam and
colleagues reported a median OS of 13 months in 21
patients who received trastuzumab after diagnosis of
mCNS disease compared with 4 months in those (n =
35) who did not receive trastuzumab after diagnosis and
3 months in 70 BM patients with HER2-negative tumors
(p = 0.0011) [26]. Bartsch and colleagues also analyzed
the effect of the continuation of trastuzumab after diag-
nosis of BM for 17 patients, in comparison with a
cohort of 36 pts with HER2 overexpressing tumors not
treated with trastuzumab after WBRT [20]. In this
report, KPS and trastuzumab were associated with better
overall survival, with a trend towards longer time to in-
brain progression. Our results confirm the fact that tras-
tuzumab-treated HER2-positive breast cancer patients
with BM fare better than HER2-negative breast cancer
patients and patients with HER2-positive tumors who
do not receive trastuzumab [20-26]. In agreement with
three previous reports, this survival advantage for
patients with brain metastases from tumors that overex-
press HER2 does not seem to be due to an intrinsic bio-
logic advantage of HER2 overexpression, as patients
with HER2-overexpressing tumors who did not receive
trastuzumab had survival similar to that of patients with
tumors that did not overexpress HER2 [23,26,33]. In our
experience, about 60% of HER-2 positive patients
HER-2 positive patients treated with trastuzumab; n=32
HER-2 negative patients, n=78
HER-2 positive patients not treated with trastuzumab ; n=20
P< 0.004
Figure 1 Survival curves according to HER-2 status and delivery of trastuzumab-based therapy.
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Page 6 of 9treated with trastuzumab who died apparently suc-
cumbed from CNS progression. Similarly, in a retro-
spective series of 122 patients treated with trastuzumab
between 1998 and 2000 at Dana-Farber/Partners Cancer
Care, about 50% of the 21 patients with brain metastases
who died apparently succumbed from CNS progression,
despite stable or responsive non-CNS disease [34].
These results suggest that HER2 targeting may improve
brain metastasis outcomes through durable control of
systemic extracranial disease in HER2-positive breast
cancer patients [35]. However, one should keep in mind
that the determination of the cause of death is difficult
in this context. As systemic therapies improve, there is
concern that the incidence of symptomatic brain metas-
tases will increase, and that control of CNS disease will
become a more vital component of overall disease con-
trol and quality of life. Althought the clinical activity of
trastuzumab on brain metastases remains debated, tras-
tuzumab may cross the blood-brain barrier when its
permeability is increased, as it occurs during WBRT
[36]. Preclinical results also found that trastuzumab may
act synergistically with radiation in a HER2 level-depen-
dent manner [37], encouraging further assessment in
combination with WBRT. Chargari and colleagues
reported preliminary results of WBRT with concurrent
trastuzumab for treatment of BM in 31 BC patients
[38]. After WBRT, radiologic responses were observed
in 23 patients (74.2%), including 6 (19.4%) with a com-
plete radiologic response and 17 (54.8%) with a partial
radiologic response. No Grade 2 or greater acute toxicity
was observed. The median survival time from the start
of WBRT was 18 months [range, 2-65] and the median
interval to brain progression was 10.5 months [range, 2-
27]. By dual inhibition of HER1 and HER2, lapatinib
also demonstrated a modest efficacy in HER2-positive
breast cancer patients with brain metastases [39]. How-
ever, Lin et al. found that up to 20% patients with CNS
progression after cranial radiation receiving lapatinib
and capecitabine experience an objective response [40].
Lapatinib is currently under investigation in combina-
tion with WBRT in an ongoing, phase I trial [41]. A
phase II study is also currently assessing the efficacy and
Table 3 Predictors of overall survival in patients with brain metastases from breast cancer (univariate analyses)
Covariate Comparison Hazard Ratio
[CI 95%]
P
N = 130
Age at BM diagnosis ≥ 50 Vs. < 50 1.21 [0.80; 1.81] 0.329
KPS ≥ 70 vs. < 70 0.51 [0.34; 0.77] 0.0013
RTOG RPA class III vs. I-II 1.98 [1.32; 2.98] 0.0013
Time interval (y) between primary tumor and BM diagnosis ≥ 2 vs. < 2 3.76 [0.52; 27.18] 0.968
Brain metastases Presence of systemic metastases vs. Alone 1.52 [0.62; 3.74] 0.366
Visceral metastases Yes vs No 1.34 [0.84; 2.11] 0.2159
Bone metastases Yes vs No 1.07 [0.71; 1.60] 0.745
No. of BM Multiple vs. single 1.12 [0.41; 3.06] 0.822
Nb of other metastatic sites Multiple vs. single 1.516 [0.6148; 3.74] 0.3627
Histology lobular and other vs. ductal 0.77 [0.34; 1.77] 0.545
Tumor HR status Negative vs. positive 1.37 [0.91; 2.06] 0.127
HER-2 overexpression Negative vs. positive 1.48 [0.98; 2.24] 0.0606
Trastuzumab-based therapy for HER2 overexpressing tumor Yes vs No 0.45 [0.27; 0.75] 0.001631
HR- & HER2- Yes vs No 2.17 [1.38; 3.43] 0.0006
SBR grade 3 vs. 1-2 1.59 [1.00; 2.52] 0.0484
LDH (U/L) > 500 vs. ≤ 500 2.01 [1.27; 3.16] 0.0026
Lymphocyte count > 700 vs. ≤ 700 0.58 [0.37; 0.89] 0.0138
Total radiation dose (Gy) > 30 vs. ≤ 30 1.54 [0.49; 4.91] 0.463
Abbreviations: KPS: Karnofsky performance status; HR: hormonal receptor; SBR = Scarff-Bloom-Richardson grade; HR = hormone receptor; RTOG = Radiation
Therapy Oncology Group; RPA = recursive partitioning analysis;
Table 4 Multivariate Analysis of Overall Survival, Cox Model (n = 130)
Covariate Comparison Hazard Ratio for death
[CI 95%]
P
N = 127
HER-2 positive patients treated with trastuzumab Yes vs No 0.49 [0.29;0.83] 0.00810
KPS ≥ 70 vs. < 70 0.56 [0.37; 0.85] 0.00578
Abbreviations: KPS: Karnofsky performance status
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by combination capecitabine and sunitinib for treatment
of brain metastases from breast cancer [42]. Concurrent
chemoradiation is also currently being investigated with
the aim of improving the control rate of both cerebral
and systemic disease [39,43]. Regarding WBRT fractio-
nation, several trials have examined the influence of the
dose, timing and fractionation of WBRT, without identi-
fying a clearly superior schedule [11]. The most widely
used WBRT regimen delivers 30 Gy in ten 3-Gy frac-
tions, but this may be inadequate for long-term tumor
control. Li et al. recently examined the outcomes of 208
patients who received WBRT as 10 daily 3-Gy fractions
in the control arm of the PCI-P120-9801 phase III trial
of motexafin gadolinium [44]. Neurocognitive function
(NCF) and survival were compared in 135 patients
assessable at 2 months with tumor shrinkage below
(poor responders) and above (good responders) the
population median (45%) on MRI. Good responders sur-
vived significantly longer than poor responders (median
300 ± 26 vs 240 ± 19 days; p = .03), and had a longer
median time before NCF deterioration, supporting the
use of techniques to maximize intracranial control, par-
ticularly for patients with HER-2-overexpressing tumors
treated with trastuzumab. In our experience, BM
patients with HER-2 overexpressing tumors treated with
trastuzumab can expect a median overall survival time
of about 20 months and a 1-year survival rate of about
60%. This subgroup of patients may therefore have a
higher risk of experiencing late radiation-related toxicity
such as neurocognitive dysfunction, and might benefit
from longer-course WBRT with lower doses per fraction
[45]. Further studies of more aggressive local therapy
with different dose and fractionation schedules, in a
manner that could minimize late effects, could probably
be more efficient for this subgroup of patients supposed
to have longest median survival.
The combination of a tumor type that has a high
potential for CNS spread and a treatment that does
n o tp e n e t r a t et h eC N Sb u ti sv e r ye f f e c t i v eo u t s i d eo f
the CNS creates the opportunity for CNS disease to
become a major clinical problem. As an example, the
introduction of trastuzumab has altered the natural
history of patients with HER2-positive breast cancer,
and unmasked CNS metastases as a potential sanctuary
site. It is anticipated that this HER2 paradigm is
applicable across tumor types, as patients live longer
with advanced cancer. In the next decade, there will be
a greater need to conduct carefully designed trials of
both cytotoxic chemotherapeutic agents and targeted
agents, either alone, or in combination, with specific
CNS end points.
Conclusions
In conclusion, BM patients with breast cancer are an
heterogenous group of patients. BM patients with HER-
2 overexpressing tumors treated by trastuzumab appears
to be a clearly distinct subroup of patients who can
expect a median survival time of about 20 months and
a1-year survival rate of 60%. This information may be
useful to tailor the therapy for subgroups of patients, to
define homogeneous cohorts for prospective randomized
trials, and to identify more precisely patients with rela-
tive good prognosis who could be treated with innova-
tive approaches, in order to obtain better intra cerebral
control, in a manner that could minimize late effects.
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